Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
News
Weed Week: France temporarily overturns CBD ban and Canada gets a classy culinary cannabis facility
Health & Biotech
Weed Week: Cannabis compounds could prevent Covid and Quebec’s no-jab, no-weed rule quadruples vaccinations
News
Winners List: Here are the top 100 ASX small cap stocks for 2021
News
Twiggy’s big 2021: From hydrogen to cannabis, nickel, retreat spas and… cheese?
Health & Biotech
What’s the best pot stock of 2021? And who’s targeting market domination in 2022?
Health & Biotech
ASX Health Stocks: Emyria to create wearable device for psychedelics, while Telix gets FDA nod
Health & Biotech
ASX Health Stocks: The TGA rejects MMDA and magic mushrooms, deals blow to ASX psychedelic players
News
November Winners: ASX investors were spooked by Omicron, but wooed by Julimar, hydrogen and the metaverse
News
Weekly Small Cap and IPO Wrap: How did this week’s five IPOs perform?
Health & Biotech
Weed Week: Uber Eats enters Canada’s cannabis market and Montu breaks crowdfunding records
News
Closing Bell: ASX feels the pinch as oil prices drop
Health & Biotech
ASX Health: Twiggy Forrest’s investment fund takes a stake in this ASX cannabis stock
Health & Biotech
ASX Health Stocks: Alterity moves to Phase 2 on cancer drug, Race Oncology secures 6th US patent
Health & Biotech
Dr Boreham’s Crucible: 4 ASX stocks focused on a mind-altering $25 billion psilocybin market
Health & Biotech
The TGA could soon relax rules on psychedelics. Here are the ASX stocks that could benefit
Health & Biotech
ASX Health Stocks: Imugene granted Japan patent, share price is now up 50% in a month
Health & Biotech